Publish Date: February 2013 Report Format: PDF
Global Markets Direct’s, 'Inflammatory Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Pain. Inflammatory Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
A snapshot of the global therapeutic scenario for Inflammatory Pain.
A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Inflammatory Pain pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.
Reasons to Buy
Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3 Inflammatory Pain Snapshot
3.1 Business Description
4 Inflammatory Pain- Research and Development Overview
4.1 Key Therapeutic Areas
5 Inflammatory Pain- Pipeline Review
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 Inflammatory Pain Pipeline Products Glance
6.1 Inflammatory Pain Phase II Pipeline
6.2 Inflammatory Pain Phase I Pipeline
6.3 Inflammatory Pain Pre-Clinical Pipeline
7 Inflammatory Pain - Drug Profiles
7.1 Product 1
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 Inflammatory Pain Pipeline Analysis
8.1 Inflammatory Pain Pipeline Products by Therapeutic Class
8.2 Inflammatory Pain Pipeline Products by Target
8.3 Inflammatory Pain Pipeline by Route of Administration
8.4 Inflammatory Pain Pipeline Products by Molecule Type
9 Inflammatory Pain- Recent Pipeline Updates
10 Inflammatory Pain- Dormant Pipeline Projects
10.1 Feature on Dormant Projects
11 Inflammatory Pain- Discontinued Pipeline Products
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product 1
12 Inflammatory Pain – Featured News
13 Inflammatory Pain Statement
13.1 Inflammatory Pain - Locations and Subsidiaries
14.1 Global Markets Direct Research Methodology
14.3 Secondary Research
14.4 Primary Research
14.6 Expert Panels
14.7 Contact Us
List of Figures
1.2 List of Figures
Figure 1: Inflammatory Pain - Research and Development Overview
Figure 2: Inflammatory Pain - Pipeline by Stage of Development, 2013
Figure 3: Inflammatory Pain - Monotherapy Products in Pipeline, 2013
Figure 4: Inflammatory Pain - Combination Treatment Modalities in Pipeline, 2013
Figure 5: Inflammatory Pain - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Inflammatory Pain - Pipeline By Therapeutic Class
Figure 7: Inflammatory Pain - Pipeline By Target and Stage of Development
Figure 8: Inflammatory Pain - Pipeline By Target
Figure 9: Inflammatory Pain - Pipeline By Route of Administration and Stage of Development
Figure 10: Inflammatory Pain - Pipeline By Route of Administration
Figure 11: Inflammatory Pain - Pipeline By Molecule Type and Stage of Development
Figure 12: Inflammatory Pain - Pipeline By Molecule Type
List of Tables
1.1 List of Tables
Table 1: Inflammatory Pain - Key Information
Table 2: Inflammatory Pain - Key Facts
Table 3: Inflammatory Pain - Key Therapeutic Areas
Table 4: Inflammatory Pain - Pipeline by Stage of Development, 2013
Table 5: Inflammatory Pain - Monotherapy Products in Pipeline, 2013
Table 6: Inflammatory Pain - Combination Treatment Modalities in Pipeline, 2013
Table 7: Inflammatory Pain - Phase II Pipeline, 2013
Table 8: Inflammatory Pain - Phase I Pipeline, 2013
Table 9: Inflammatory Pain - Pre-Clinical Pipeline, 2013
Table 10: Inflammatory Pain - Pipeline By Therapeutic Class
Table 11: Inflammatory Pain - Pipeline By Target
Table 12: Inflammatory Pain - Pipeline By Route of Administration
Table 13: Inflammatory Pain - Pipeline By Molecule Type
Table 14: Inflammatory Pain - Recent Pipeline Updates
Table 15: Inflammatory Pain - Dormant Pipeline Projects